Biomea Fusion Inc banner

Biomea Fusion Inc
NASDAQ:BMEA

Watchlist Manager
Biomea Fusion Inc Logo
Biomea Fusion Inc
NASDAQ:BMEA
Watchlist
Price: 1.31 USD -2.96%
Market Cap: $92.6m

During the last 3 months Biomea Fusion Inc insiders bought 196.7k USD , and have not sold any shares. The stock price has dropped by 4% over this period (open performance analysis).

The last transaction was made on Dec 11, 2025 by Erdtmann Rainer M , who bought 43k USD worth of BMEA shares.

Last Transactions:
Erdtmann Rainer M
$+43k
Hitchcock Michael J.m.
$+99.2k
Erdtmann Rainer M
Chief Financial Officer
$+10.5k
Erdtmann Rainer M
Chief Financial Officer
$+44.1k
Hitchcock Michael J.m.
$+100.6k
Valle Franco
$+55.4k
A2A Pharmaceuticals, Inc.
$-1.7m
A2A Pharmaceuticals, Inc.
$-2.5m
A2A Pharmaceuticals, Inc.
$-846k
A2A Pharmaceuticals, Inc.
$-5.2m
A2A Pharmaceuticals, Inc.
$-3.4m
A2A Pharmaceuticals, Inc.
$-5.8m
A2A Pharmaceuticals, Inc.
$-6.3m
Cormorant Asset Management, Lp
$+12m
Hitchcock Michael J.m.
$+39.7k
Valle Franco
$+31.3k
A2A Pharmaceuticals, Inc.
$+425.6k
A2A Pharmaceuticals, Inc.
$-388.5k
A2A Pharmaceuticals, Inc.
$-407.6k
Valle Franco
$+86.8k
Stergiopoulos Sotirios
$+379.9k
A2A Pharmaceuticals, Inc.
$+379.9k
Butler Thomas Andrew
$+316.9k
Erdtmann Rainer M
$+316.9k
Butler Thomas Andrew
$+150.7k
Erdtmann Rainer M
$+150.7k
Butler Thomas Andrew
$+151.1k
Erdtmann Rainer M
$+151.1k
Cormorant Asset Management, Lp
$+15.3m
Erdtmann Rainer M
$+40.8k
Butler Thomas Andrew
$+3m
Erdtmann Rainer M
$+3m
View All Transactions

During the last 3 months Biomea Fusion Inc insiders bought 196.7k USD , and have not sold any shares. The stock price has dropped by 4% over this period (open performance analysis).

The last transaction was made on Dec 11, 2025 by Erdtmann Rainer M , who bought 43k USD worth of BMEA shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
0 USD
0
Bought
0-3
months
2
196.7k USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
No Insider Transactions
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Biomea Fusion Inc
Insider Trading Chart

Biomea Fusion Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Biomea Fusion Inc
Last Insider Transactions

Global
Insiders Monitor

Biomea Fusion Inc
Glance View

Market Cap
92.6m USD
Industry
Biotechnology

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. The company is headquartered in Redwood City, California and currently employs 51 full-time employees. The company went IPO on 2021-04-16. The firm is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The firm has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The firm's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The firm is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The firm is also advancing other preclinical irreversible programs for the treatment of select cancers.

BMEA Intrinsic Value
HIDDEN
Show

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top